Aarti Pharmalabs Limited Cash Flow Conversion Efficiency

Latest as of September 2023: 0.022x

Aarti Pharmalabs Limited cash flow conversion efficiency. Based on the latest financial reports, Aarti Pharmalabs Limited (AARTIPHARM) has a cash flow conversion efficiency ratio of 0.022x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs362.80 Million ≈ $3.92 Million USD) by net assets (Rs16.58 Billion ≈ $179.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Aarti Pharmalabs Limited (2020–2025)

Cash flow conversion efficiency of Aarti Pharmalabs Limited from 2020 to 2025. This chart illustrates how Aarti Pharmalabs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Aarti Pharmalabs Limited (AARTIPHARM) stock price for real-time trading data and today's change.

Aarti Pharmalabs Limited Cash Flow Conversion Ratio Explained

Aarti Pharmalabs Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Aarti Pharmalabs Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Aarti Pharmalabs Limited ranked by their cash flow conversion efficiency. Also see Aarti Pharmalabs Limited market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
AB SKF (publ) ST:SKF-A	0.034x
Plazza AG SW:PLAN	0.016x
Southside Bancshares, Inc. NASDAQ:SBSI	0.048x
Sichuan Xunyou Network Technology Co Ltd SHE:300467	0.041x
Shanghai Shibei Hi-Tech Co Ltd A SHG:600604	0.007x
PPHE Hotel Group Ltd F:32P	0.024x
Kura Oncology Inc NASDAQ:KURA	-1.292x
Odyssey Therapeutics, Inc. Common Stock NASDAQ:ODTX	-0.082x

Annual Cash Flow Conversion Efficiency for Aarti Pharmalabs Limited (2020–2025)

The table below shows the annual cash flow conversion efficiency of Aarti Pharmalabs Limited from 2020 to 2025. Review how much free cash does Aarti Pharmalabs Limited generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	Rs19.90 Billion ≈ $215.20 Million	Rs3.32 Billion ≈ $35.86 Million	0.167x	+35.32%
2024-03-31	Rs17.57 Billion ≈ $190.02 Million	Rs2.16 Billion ≈ $23.40 Million	0.123x	-27.03%
2023-03-31	Rs15.58 Billion ≈ $168.54 Million	Rs2.63 Billion ≈ $28.44 Million	0.169x	+635.36%
2022-03-31	Rs13.86 Billion ≈ $149.94 Million	Rs-437.04 Million ≈ $-4.73 Million	-0.032x	--
2021-03-31	Rs2.27 Million ≈ $24.52K	Rs0.00 ≈ $0.00	0.000x	--
2020-03-31	Rs2.31 Million ≈ $25.02K	Rs-186.75K ≈ $-2.02K	-0.081x	--

About Aarti Pharmalabs Limited

NSE:AARTIPHARM India Drug Manufacturers - Specialty & Generic

Market Cap

$871.30 Million

Rs80.57 Billion INR

Market Cap Rank

#9181 Global

#454 in India

Share Price

Rs888.80

Change (1 day)

+1.84%

52-Week Range

Rs591.95 - Rs975.00

All Time High

Rs975.00